Rapid communication Open Access
Like 0


With numbers of COVID-19 cases having substantially increased at the end of 2022 in China, some countries have started or expanded testing and genomic surveillance of travellers. We report screening results in Italy in late December 2022 of 556 flight passengers in provenance from two Chinese provinces. Among these passengers, 126 (22.7%) tested SARS-CoV-2 positive. Whole genome sequencing of 61 passengers’ positive samples revealed Omicron variants, notably sub-lineages BA.5.2.48, BF.7.14 and BQ.1.1, in line with data released from China.


Article metrics loading...

Loading full text...

Full text loading...



  1. Owens D, Parry J. Covid-19: What can China learn from Hong Kong and Singapore about exiting zero covid? BMJ. 2022;379:o3043.  https://doi.org/10.1136/bmj.o3043  PMID: 36543337 
  2. European Centre for Disease Prevention and Control (ECDC). Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA. Stockholm: ECDC; 3 Jan 2023. Available from: https://www.ecdc.europa.eu/en/news-events/impact-surge-china-covid-19-cases
  3. Leung K, Lau EHY, Wong CKH, Leung GM, Wu JT. Estimating the transmission dynamics of Omicron in Beijing, November to December 2022. medRxiv. 2022; 12.28.
  4. Centers for Disease Control and Prevention (CDC). CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People’s Republic of China. Atlanta: CDC; 28 Dec 2022. Available from: https://www.cdc.gov/media/releases/2022/p1228-COVID-china.html
  5. Covid in China. US imposes Covid testing for visitors from China; 29 Dec 2022. [Accessed: 19 Dec 2022]. Available from: https://www.bbc.com/news/world-asia-china-64111492
  6. Ministerio della Salute. COVID-19, travellers. The measures for entry into Italy. [Accessed 10 Jan 2023]. Available from: https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=english&id=5412&area=nuovoCoronavirus&menu=vuoto
  7. World Health Organization (WHO). TAG-VE statement on the meeting of 3 January on the COVID-19 situation in China. Geneva: WHO; 4 Jan 2023. Available from: https://www.who.int/news/item/04-01-2023-tag-ve-statement-on-the-3rd-january-meeting-on-the-covid-19-situation-in-china
  8. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022;19:12.  https://doi.org/10.1038/s41586-022-05644-7  PMID: 36535326 
  9. Jian F, Yu Y, Song W, Yisimayi A, Yu L, Gao Y, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. Lancet Infect Dis. 2022;22(11):1535-7.  https://doi.org/10.1016/S1473-3099(22)00642-9  PMID: 36179744 
  10. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, et al. Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666-8.  https://doi.org/10.1016/S1473-3099(22)00694-6  PMID: 36328002 
  11. Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB. bioRxiv. 2022; 11.25.
  12. Arshad N, Laurent-Rolle M, Ahmed WS, Hsu JCC, Mitchell SM, Pawlak J, et al. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. Proc Natl Acad Sci U S A. 2023;120(1):e2208525120.  https://doi.org/10.1073/pnas.2208525120  PMID: 36574644 
  13. Zheng S, de Buhr H, Praest P, Evers A, Brak-Boer I, van Grinsven M, et al. The SARS-CoV-2 accessory factor ORF7a downregulates MHC class I surface expression. bioRxiv. 2022: 05.29 . https://doi.org/10.1101/2022.05.29.493850 
  14. Pawlica P, Yario TA, White S, Wang J, Moss WN, Hui P, et al. SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. Proc Natl Acad Sci U S A. 2021;118(52):e2116668118.  https://doi.org/10.1073/pnas.2116668118  PMID: 34903581 
  15. Hassan SS, Choudhury PP, Dayhoff GW 2nd, Aljabali AAA, Uhal BD, Lundstrom K, et al. The importance of accessory protein variants in the pathogenicity of SARS-CoV-2. Arch Biochem Biophys. 2022;717:109124.  https://doi.org/10.1016/j.abb.2022.109124  PMID: 35085577 
  16. covSPECTRUM. ORF7a:S44P search from 2022-07-11 to 2023-01-04. Available from: https://cov-spectrum.org/explore/World/AllSamples/Past6M/variants?aaMutations=ORF7a%3AS44P&
  17. covSPECTRUM. ORF7a:T61S search from 2022-07-11 to 2023-01-04. Available from: https://cov-spectrum.org/explore/World/AllSamples/Past6M/variants?aaMutations=ORF7a%3AT61S&
  18. Lobiuc A, Șterbuleac D, Sturdza O, Dimian M, Covasa M. A conservative replacement in the transmembrane domain of SARS-CoV-2 ORF7a as a putative risk factor in COVID-19. Biology (Basel). 2021;10(12):1276.  https://doi.org/10.3390/biology10121276  PMID: 34943191 
  19. Mainland China. the latest coronavirus counts, charts and maps. [Accessed: 29 Dec 2022]. Available from: https://www.reuters.com/graphics/world-coronavirus-tracker-and-maps/countries-and-territories/china
  20. China Covid: What is China’s policy and how many cases are there? BBC: Reality check. [Accessed: 20 Dec 2022]. Available from: https://www.bbc.com/news/59882774..
  21. Tan CY, Chiew CJ, Lee VJ, Ong B, Lye DC, Tan KB. Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore. Lancet Reg Health West Pac. 2022;29:100654.  https://doi.org/10.1016/j.lanwpc.2022.100654  PMID: 36471699 
  22. Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, et al. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. Clin Infect Dis. 2022;75(8):1442-5.  https://doi.org/10.1093/cid/ciac288  PMID: 35412612 
  23. COVID-19 projections in China by Institute for Health Metrics and Evaluation at the University of Washington, Seattle. [Accessed: 4 Jan 2023]. Available from: https://covid19.healthdata.org/china?view=mask-use&tab=trend

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error